# US 2023/0417763 A1 · Method of determining toxicity of an immunomodulatory drug for use in humans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0417763 A1
- Document ID: US20230417763A1
- Status: Published application
- Kind: A1
- Application number: 18/341,029
- Filed: 2023-06-26
- Published: 2023-12-28
- Earliest claimed: 2017-04-17
- Assignees: The Jackson Laboratory
- Applicants: The Jackson Laboratory
- Inventors: James Keck; Chunting Ye
- Web page: https://patentgrep.com/patent/US20230417763A1

## CPC

- G01N 33/5044: {involving specific cell types}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2887: {against CD20}
- C07K 16/2893: {against CD52}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2217/15: Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A01K 2227/105: Murine
- A01K 2267/0325: Animal model for autoimmune diseases
- G01N 2800/24: Immunology or allergic disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

A method for assessing immune toxicity of an immunomodulatory agent, the method comprising:
(a) administering human peripheral blood mononuclear cells (PBMCs) to an immunodeficient mouse that has been subjected to myeloablation;
(b) administering an immunomodulatory agent to the immunodeficient mouse; and
(d) measuring blood concentration of a human cytokine selected from interferon-gamma (IFN-γ), interleukin (IL)-10, IL-6, IL-2, IL-4, and tumor necrosis factor alpha (TNFα) in a sample from the immunodeficient mouse before the mouse develops a symptom of graft versus host disease (GVHD), wherein blood concentration of the cytokine equal to or above a threshold concentration value is indicative of immune toxicity of the immunomodulatory agent.

### Claim 55 (depends on 54)

The method of claim 54, wherein the symptom of GVHD is significant weight loss.

### Claim 56 (depends on 54)

The method of claim 54, wherein the myeloablation comprises irradiation.

### Claim 57 (depends on 54)

The method of claim 54, wherein 1.5×107-3.0×107 human PBMCs are administered to the immunodeficient mouse.

### Claim 58 (depends on 54)

The method of claim 54, wherein the immunodeficient mouse has a non-obese diabetic (NOD) severe combined immunodeficiency (scid) gamma genetic background.

### Claim 59 (depends on 54)

The method of claim 54, wherein the administering an immunomodulatory agent to the immunodeficient mouse is fewer than 8 days after the administering human PBMCs to the immunodeficient mouse.

### Claim 60 (depends on 59)

The method of claim 59, wherein the administering an immunomodulatory agent to the immunodeficient mouse is 5-7 days after the administering human PBMCs to the immunodeficient mouse.

### Claim 61 (depends on 54)

The method of claim 54, wherein the measuring is within 24 hours of the administering an immunomodulatory agent to the immunodeficient mouse.

### Claim 62 (depends on 54)

The method of claim 54, wherein the immunomodulatory agent is an antibody.

### Claim 62 (depends on 54)

The method of claim 54, wherein the immunomodulatory agent is a checkpoint inhibitor.

### Claim 63 (depends on 62)

The method of claim 62, wherein the antibody is a monoclonal antibody.

### Claim 63 (depends on 62)

The method of claim 62, wherein the checkpoint inhibitor is selected from cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, programmed death-1 (PD-1) inhibitors, and programmed death-ligand 1 (PD-L1) inhibitors.

### Claim 64 (depends on 63)

The method of claim 63, wherein the checkpoint inhibitor is selected from ipilimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, and durvalumab.

### Claim 65 (depends on 54)

The method of claim 54, wherein the threshold concentration value for IFN-γ, IL-10, IL-6, IL-2, IL-4, and TNFα is respectively 1,800 pg/ml, 120 pg/ml, 25 pg/ml, 80 pg/ml, 25 pg/ml, and 20 pg/ml.

### Claim 66

A method for assessing immune toxicity of an immunomodulatory agent, the method comprising:
(a) administering human peripheral blood mononuclear cells (PBMCs) to an immunodeficient mouse that has been irradiated;
(b) administering an immunomodulatory agent to the immunodeficient mouse fewer than 8 days after the administering human PBMCs; and
(d) measuring blood concentration of a human cytokine selected from interferon-gamma (IFN-γ), interleukin (IL)-10, IL-6, IL-2, IL-4, and tumor necrosis factor alpha (TNFα) in a sample from the immunodeficient mouse before the mouse develops a symptom of graft versus host disease (GVHD), wherein the symptom of GVHD is significant weight loss, and
wherein blood concentration of the cytokine equal to or above a threshold concentration value is indicative of immune toxicity of the immunomodulatory agent.

### Claim 67 (depends on 66)

The method of claim 66, wherein 1.5×107-3.0×107 human PBMCs are administered to the immunodeficient mouse.

### Claim 68 (depends on 66)

The method of claim 66, wherein the administering an immunomodulatory agent to the immunodeficient mouse is 5-7 days after the administering human PBMCs to the immunodeficient mouse.

### Claim 69 (depends on 66)

The method of claim 66, wherein the measuring is within 24 hours of the administering an immunomodulatory agent to the immunodeficient mouse

### Claim 70 (depends on 66)

The method of claim 66, wherein the immunomodulatory agent is an antibody.

### Claim 71 (depends on 66)

The method of claim 66, wherein the threshold concentration value for IFN-γ, IL-10, IL-6, IL-2, IL-4, and TNFα is respectively 1,800 pg/ml, 120 pg/ml, 25 pg/ml, 80 pg/ml, 25 pg/ml, and 20 pg/ml.
